Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Decreased by Czech National Bank

Czech National Bank lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,588 shares of the biopharmaceutical company’s stock after selling 178 shares during the quarter. Czech National Bank’s holdings in Regeneron Pharmaceuticals were worth $17,891,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Fortitude Family Office LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $31,000. MCF Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 12 shares in the last quarter. Criterion Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $37,000. Bruce G. Allen Investments LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $40,000. Finally, AllSquare Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89.7% in the 3rd quarter. AllSquare Wealth Management LLC now owns 55 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 26 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now directly owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the company’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,397,202. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now directly owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. In the last 90 days, insiders sold 61,215 shares of company stock valued at $60,414,782. Insiders own 7.48% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on REGN. Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target on the stock. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a report on Wednesday, March 13th. TD Cowen upped their target price on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. JPMorgan Chase & Co. lifted their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Bank of America upped their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $998.09.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of NASDAQ REGN traded up $5.28 during trading hours on Thursday, hitting $1,044.39. The stock had a trading volume of 590,553 shares, compared to its average volume of 469,702. The firm’s 50-day moving average price is $964.87 and its two-hundred day moving average price is $941.08. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $1,052.34. The company has a market capitalization of $115.08 billion, a P/E ratio of 30.85, a P/E/G ratio of 2.15 and a beta of 0.13. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.